X Close
Online Enquiry
Name *
Phone *
Email *
* Required fields

Contact Us

If you have any questions or enquiries please feel free to contact us on the following details provided below or alternatively please complete our online enquiry form also located below and we will get back to you as soon as possible.

IMPORTANT: This contact form is for NON-URGENT general enquiries only and is not suitable for medical enquiries or booking appointments.


03 5981 1000




Shingles vaccine

There are two zoster vaccines now available for use in adults aged ≥50 years in Australia to prevent herpes zoster 

  • Zostavax (Merck) is a live-attenuated varicella zoster virus vaccine. Zostavax requires a single dose.
  • Shingrix (GlaxoSmithKline) is an adjuvanted recombinant varicella zoster virus glycoprotein E (gE) subunit (non-live) vaccine. Shingrix requires two doses, with an interval of 2-6 months between doses.
  • Shingrix is preferred over Zostavax from age 50 years and above for prevention of herpes zoster and its complications, due to its higher efficacy. Shingrix is now available in Australia through private prescription only. It is not available through the NIP.
  • Zostavax remains a readily available and effective alternative vaccine for immunocompetent adults aged ≥50 years who wish to reduce their risk of herpes zoster. It is recommended and funded under the National Immunisation Program (NIP) for immunocompetent people aged 70 years of age (with catch-up for those aged 71-79 years until October 2023).

Zostavax® provided free for 70-79 year olds until October 2023

The shingles vaccine, Zostavax®, has been approved to be placed on the National Immunisation Program (NIP), to be provided free of charge from 1 November 2016 to people aged 70 years.